Cargando…
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in reducing the risk of atrial fibrillation (AF). However, the results are controversial and the underlying metabolic mechanism remains unclear. Emerging evidence implied that SGLT2 inhibitors have extra beneficial meta...
Autores principales: | Li, Jiang, Yu, Yuefeng, Sun, Ying, Yu, Bowei, Tan, Xiao, Wang, Bin, Lu, Yingli, Wang, Ningjian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583416/ https://www.ncbi.nlm.nih.gov/pubmed/37848934 http://dx.doi.org/10.1186/s12933-023-02019-8 |
Ejemplares similares
-
Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
por: Yu, Yuetian, et al.
Publicado: (2023) -
SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study
por: Xu, Min, et al.
Publicado: (2022) -
Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation
por: Bode, David, et al.
Publicado: (2021) -
Circulating Vitamin D Levels and the Risk of Atrial Fibrillation: A Two-Sample Mendelian Randomization Study
por: Yang, Shengyi, et al.
Publicado: (2022) -
Education and Atrial Fibrillation: Mendelian Randomization Study
por: Liu, Yaozhong, et al.
Publicado: (2022)